Frontiers in Bioengineering and Biotechnology · Nov 18, 2026
Modified mRNA as a Pulsed Targeting for Cardiac Repair: Opportunities and Translational Hurdles
By Yongyu Wang, Minjie Hu, Yalin Wu et al.
From the molecular and cellular perspective, heart failure occurs due to the loss of the contractile unit of the left ventricle: cardiomyocytes (CMs). Thus, methods for remuscularizing the myocardium via the administration of exogenous cells or by inducing the proliferation of pre-existing CMs are increasingly compelling topics of investigation. Cell-based approaches offer the most direct route to remuscularization but face challenges of low engraftment efficiency and electrical coupling with native myocardium. Cell-free strategies, including recombinant proteins, viral gene delivery, bypass engraftment barriers but each carry distinct limitations: recombinant proteins have short half-lives and poor cellular uptake; viral DNA vectors carry potential genomic integration risks and pre-existing immune neutralization. RNA-based therapies bypass the low engraftment rate of cell therapy, because they are taken up by cells that are already present in the myocardium, and since RNA cannot integrate with the cellular genome, the risk of long-term side-effects is low. Furthermore, chemotopological alterations to the native transcript can alleviate the intrinsic instability and immunogenicity of naturally occurring mRNA, thereby producing modified mRNAs (modRNAs) that can be used to promote CM proliferation or vascular growth, reduce apoptosis and fibrosis, or reprogram fibroblasts into CM-like cells. Ongoing advances in cell-type-specific translation systems, delivery formulation engineering, and room-temperature-stable preparations are accelerating the clinical translation of this emerging class of cardiovascular therapeutics.